Compare JAZZ & DECK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JAZZ | DECK |
|---|---|---|
| Founded | 2003 | 1973 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Shoe Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1B | 14.2B |
| IPO Year | 2007 | 1996 |
| Metric | JAZZ | DECK |
|---|---|---|
| Price | $247.13 | $93.69 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 23 |
| Target Price | ★ $217.57 | $122.45 |
| AVG Volume (30 Days) | 702.7K | ★ 2.1M |
| Earning Date | 05-05-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.90 |
| EPS | ★ 7.17 | 0.94 |
| Revenue | $1,618,693,000.00 | ★ $5,472,296,000.00 |
| Revenue This Year | $6.22 | $11.16 |
| Revenue Next Year | $7.68 | $6.96 |
| P/E Ratio | ★ $35.67 | $103.59 |
| Revenue Growth | N/A | ★ 9.76 |
| 52 Week Low | $112.53 | $78.91 |
| 52 Week High | $265.05 | $125.45 |
| Indicator | JAZZ | DECK |
|---|---|---|
| Relative Strength Index (RSI) | 49.34 | 35.56 |
| Support Level | $222.49 | $92.22 |
| Resistance Level | $250.49 | $106.24 |
| Average True Range (ATR) | 7.19 | 3.42 |
| MACD | -0.96 | -0.45 |
| Stochastic Oscillator | 15.93 | 12.27 |
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Founded in 1973, California-based Deckers designs and sells casual and performance footwear, apparel, and accessories. In fiscal 2026, Ugg and Hoka accounted for 50% and 47% of total sales, respectively. The firm also markets a niche sandal brand Teva. Deckers produces most of its sales through wholesale partnerships but also operates e-commerce in more than 50 countries and has more than 200 company-operated stores, about half of which are outlets. The firm generated 58% of its fiscal 2026 sales in the United States.